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Aim of the study
Identification of genetic variations in genes related to
metabolism of selenium, including glutathione peroxi-
dases (GPX) and thioredoxin reductases (TXNRD) as
markers for breast cancer and/or ovarian cancer risks in
carriers of BRCA1 gene mutation: analysis of selected
changes in the subgroups, depending on the plasma
selenium concentration.
Material and methods
A group of 50 newly diagnosed breast and/or ovarian
cancer patients carrying BRCA1 mutation was analyzed
by exon-by-exon sequencing of 3 genes (GPX1, GPX4,
TXNRD2) coding selenoproteins. Simultaneously a
nested case-control study of 39 women with breast can-
cer and 7 women with ovarian cancer (blood samples
for all affected carriers were collected before treatment)
and 92 controls matched 1 to 2 cases has been con-
ducted and changes detected by sequencing have been
analyzed. Additional case – control studies were per-
formed on 45 pairs 1:2 matched for GPX1 (rs1050450).
All cases and controls were matched for age at enrol-
ment, past history of breast cancer and oophorectomy.
All these patients were carriers of one of three Polish
founder BRCA1 mutation. In these patients plasma sele-
nium level has been determined.
The following techniques for laboratory analyses have
been applied:
a) sequencing on (ABI310),
b) SimpleProbe or Taqmqan analysis (a melting-curve
genotyping with fluorescence-labeled probes based on
the LightCycler 480 System (Roche Applied Science)),
c) determination of selenium concentration in plasma
using atomic absorption spectrometer AAnalyst600
(Perkin Elmer).
Results
The strongest association has been found for GPX1
(rs1050450). Multivariate statistics allowed the analysis
of each risk factor separately as well as their interac-
tion with the help of logistic regression model. Sub-
jects having plasma selenium levels under or equal 80
μg/l showed a generally decreased risk of being dis-
eased (OR=0.24; 95%Cl= 0.06-0.94; p=0.041). The gen-
otype of rs1050450 in the gene GPX1 was not a risk
factor for itself (p=0.70). However, when analyzed in
combination, an interaction effect could be proven
where carriers of the minor allele of rs1050450 having
plasma selenium levels above or equal 80µg/l were
under an increased disease risk (OR=6.24; 95%Cl=1.09-
36; p=0.040).
This effect was even more exacerbated among those
women which joined the study after adnexectomy
(OR=29.2; 95%Cl= 1.6-2000; p=0.0076), while among
women without adnexectomy the effect could not be
detected at all (OR=2.27; 95%Cl= 0.30-27.8; p=0.43).
Adnexectomy was not a risk factor itself in the logistic
regression model (p=0.49). Cases and controls in tri-
plets with the same genotypes of GPX1 were also
taken into account. Although no significant result was
achieved, there was a tendency for more unaffected
subjects of CC genotype-carriers in GPX1 with serum
selenium levels above or equal 80μg/l (5:14 instead of
expected 5:10). The opposite was shown for non-CC
genotype carriers in GPX1 with plasma selenium level
above or equal 80μg/l (12:18 instead of expected
12:24). * Correspondence: ka_jaworska@wp.pl
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